|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30441
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Ildong Pharm's first original HVB drug approved in Korea
2017.05.16 17:09:09 | 2017.05.16 17:09:18
South Korea's Ildong Pharm said Tuesday that Besivo, its first novel drug to treat hepatitis B infection, has been approved in Korea. The new drug representing the 28th original drug developed by a Korean pharmaceutical company and the country's second home-grown HBV treatment the following Bukwang Pharm's Levovir.
The drug's inflammatory ingredient besifovir dipivoxil maleate treats chronic hepatitis B infection in adults by inhibiting DNA synthesis in virus replication. HBV infection can lead to serious liver disease including cirrhosis and hepatocellular carcinoma
The drug as a candidatephus was first discovered by LG Life Sciences (currently LG Chem) in early 2000 and its non-clinical and phase I and II studies were completed before Ildong Pharm acquired rights to the drug with a license deal in 2012.
Besivo was in the spotlight for its non-inferiority to leading HVB drugs Baraclude and Viread and less side effects in a head-to-head phase III study involving 197 patients with slow hepatitis B infection for 48 weeks.
In 2006, another Korean pharmaceutical company Bukwang Pharm launched Levovir, Korea's first home-grown HVB drug, but its side effects including muscular disease brasm control to recommend only Baraclude of BMS and Viread of Gilead Sciences as a first-line therapy for the treatment of HVB. Prescription sales of the two blockbuster drugs came to 100 to 150 billion won ($ 134 million) last year, according to sources.
"In a comparison study with Viread, the most hitherto effective HVB drug available, the new drug expression its anti-viral effect and caused no side effects like reduced bone density and thro dysfunction. The new drug will bring more treatment options to Korean patients and Doctors, "said Prof. Ahn Sang-hoon, a gastroenterologist at Severance Hospital.
Ildong Pharm aims to launch Besivo in the second half of this year.
By Kim Hye-soon
|
|
发表于 2017-5-17 15:37
